Nov
24
2023
Kynexis sets sights on schizophrenia with $61 million
Patients are devastated,” says Kees Been, Kynexis CEO and a former Biogen exec. “They live, but they don’t have lives.” The start-up launched Nov. 7 with €57 million ($61 million)...